REBINYN (COAGULATION FACTOR IX RECOMBINANT, GLYCOPEGYLATED)
REBINYN (COAGULATION FACTOR IX RECOMBINANT, GLYCOPEGYLATED) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: REBINYN; Generic name: COAGULATION FACTOR IX RECOMBINANT, GLYCOPEGYLATED; Manufacturer: Novo Nordisk.
| Brand name | REBINYN |
|---|---|
| Generic name | COAGULATION FACTOR IX RECOMBINANT, GLYCOPEGYLATED |
| Manufacturer | Novo Nordisk |
| Used for | 1 INDICATIONS AND USAGE REBINYN, Coagulation Factor IX (Recombinant), GlycoPEGylated, is a recombinant DNA-derived coagulation Factor IX concentrate indicated for use in adults and children with hemophilia B (congenital Factor IX deficiency) for: • On-demand treatment and control of bleeding episodes • Perioperative management of bleeding • Routine prophylaxis to reduce the frequency of bleeding episodes Limitations of Use : REBINYN is not indicated for immune tolerance induction in patients with hemophilia B. REBINYN, Coagulation Factor IX (Recombinant), GlycoPEGylated, is a recombinant DNA-derived coagulation Factor IX concentrate indicated for use in adults and children with hemophilia B |
| Dosage | 2 DOSAGE AND ADMINISTRATION For intravenous infusion after reconstitution only. For intravenous infusion after reconstitution only ( 2 ). • Each carton and vial label for REBINYN states the actual Factor IX potency in international units (IU) ( 2.1 ). On-demand treatment and control of bleeding episodes: • 40 IU/kg body weight for minor and moderate bleeds, and 80 IU/kg body weight for major bleeds. Additional doses of 40 IU/kg can be given ( 2.1 ). Perioperative management: • Pre-operative dose |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0ea37235-35fd-410d-b8c4-40ba15fe1294 |